GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Integrated Biopharma Inc (OTCPK:INBP) » Definitions » Price-to-Owner-Earnings

Integrated Biopharma (Integrated Biopharma) Price-to-Owner-Earnings : (As of May. 17, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Integrated Biopharma Price-to-Owner-Earnings?

As of today (2024-05-17), Integrated Biopharma's share price is $0.22. Integrated Biopharma does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Integrated Biopharma's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Integrated Biopharma was 27.69. The lowest was 1.17. And the median was 7.57.


INBP's Price-to-Owner-Earnings is not ranked *
in the Consumer Packaged Goods industry.
Industry Median: 15.32
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-17), Integrated Biopharma's share price is $0.22. Integrated Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.00. Therefore, Integrated Biopharma's PE Ratio for today is At Loss.

As of today (2024-05-17), Integrated Biopharma's share price is $0.22. Integrated Biopharma's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.00. Therefore, Integrated Biopharma's PE Ratio without NRI for today is At Loss.

During the past 13 years, Integrated Biopharma's highest PE Ratio without NRI was 50.00. The lowest was 0.00. And the median was 4.19.


Integrated Biopharma Price-to-Owner-Earnings Historical Data

The historical data trend for Integrated Biopharma's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integrated Biopharma Price-to-Owner-Earnings Chart

Integrated Biopharma Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 12.16 8.21 4.72 15.06

Integrated Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.66 15.06 8.48 - -

Competitive Comparison of Integrated Biopharma's Price-to-Owner-Earnings

For the Packaged Foods subindustry, Integrated Biopharma's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Integrated Biopharma's Price-to-Owner-Earnings Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Integrated Biopharma's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Integrated Biopharma's Price-to-Owner-Earnings falls into.



Integrated Biopharma Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Integrated Biopharma's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.22/-0.02
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Integrated Biopharma  (OTCPK:INBP) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Integrated Biopharma Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Integrated Biopharma's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Integrated Biopharma (Integrated Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
225 Long Avenue, Building 15, Hillside, NJ, USA, 07205
Integrated Biopharma Inc is a pharmaceutical company engaged in manufacturing, distributing, marketing, and selling vitamins, nutritional supplements, and herbal products. It operates in two segments; Contract Manufacturing and Other Nutraceutical Businesses. It serves the needs of the nutraceutical industry by directly doing business as Chem International Inc. and through its operating subsidiaries; Manhattan Drug Company, Inc., AgroLabs, Inc., IHT Health Products, Inc. and MDC Warehousing and Distribution, Inc. The company generates maximum revenue from the Contract Manufacturing segment. The business operates and generates the majority of revenue from the United States.
Executives
Damon Desantis director 2424 N FEDERAL HIGHWAY, SUITE 208, BOCA RATON FL 33431
William H. Milmoe director, 10 percent owner 3299 N.W. 2ND AVENUE, BOCA RATON FL 33431
Joseph Laplaca director 72 EUGENE DRIVE, MONTVILLE NJ 07045
E Gerald Kay director, 10 percent owner, officer: Chairman and CEO C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Bradley J Hoecker director STONINGTON PARTNERS, INC., 540 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Jeffrey R Leach director, officer: President and CEO
Glenn Chang director C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Vidadi Yusibov director C/O IBIOPHARMA, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Cd Financial, Llc 10 percent owner 3299 N.W. 2ND AVENUE, BOCA RATON FL 33431
Kay Riva director, officer: Vice President C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Christina Kay director, officer: Vive President C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Robert Canarick director C/O INTEGRATED BIOPHARMA, INC., 201 ROUTE 22, HILLSIDE NJ 07205
Robert Kay director C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Dina Masi officer: Chief Financial Officer 14 LEXINGTON WAY, LONG VALLEY NJ 07853
Carl Desantis director, 10 percent owner C/O CDS INTERNATIONAL HOLDINGS, 3299 NW SECOND AVE, BOCA RATON FL 33431